Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553516 | 0.72 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL476548 | 0.70 | GAA (0.60) | ALDH1A1GSK3AGSK3BHSD17B10LMNA | |
| SCHEMBL98169 | 0.70 | — | — | |
| SCHEMBL29139900 | 0.69 | TSHR (0.39) | SMN1; SMN2ALDH1A1KDM4EHPGDMEN1 | |
| Ethylamine SCHEMBL28845358 | 0.68 | GAA (0.52) | SMN1; SMN2ALDH1A1GSK3AGSK3BHPGD | |
| SCHEMBL11217736 | 0.68 | GAA (0.57) | ALDH1A1GSK3AGSK3BKDM4EMEN1 | |
| SCHEMBL6186193 | 0.68 | — | — | |
| SCHEMBL964379 | 0.68 | GAA (0.57) | ALDH1A1GSK3AGSK3BHSD17B10LMNA | |
| SCHEMBL31197183 | 0.68 | — | — | |
| SCHEMBL7331280 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-7598391-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2009-10-06 | — | — | US | disclosed |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | NPSR1 4121/4885SMN1; SMN2 3633/4885ALDH1A1 1548/4885 |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | NPSR1 4680/4885SMN1; SMN2 3139/4885ALDH1A1 895/4885 |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | GCK, GCKR, HK1 | NPSR1 4229/4885SMN1; SMN2 2648/4885ALDH1A1 318/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | NPSR1 4790/4885SMN1; SMN2 3504/4885ALDH1A1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.